BMY’s new phase-3 Lambda trial in genotype-1b is unusual insofar as it has two variables: Lambda + Daclatasvir + ribavirin vs Pegasys + Incivek + ribavirin:
If the former arm outperforms on safety or effcacy, it won’t be clear whether to attribute the disparity to Lambda vs Pegasys or to Daclatasvir vs Incivek.
In any event, it may take a long time to enroll this trial.
Market Data 
Markets 
AI
